Anhydramnios |
| Anhydramnios
is the complete or nearly complete absence of measurable amniotic fluid
surrounding the fetus. It must be distinguished from oligohydramnios,
in which fluid is reduced but still detectable. During early gestation,
amniotic fluid is derived partly from maternal and placental sources,
but fetal urine becomes its principal component during the second
trimester. Normal volume also depends on fetal swallowing, pulmonary
fluid secretion, membrane integrity, and fluid movement across the
placenta and fetal membranes. Consequently, anhydramnios is not a
diagnosis by itself but a manifestation of an underlying fetal,
placental, or membrane disorder. The timing, cause, and duration of anhydramnios largely determine its consequences. Early pregnancy renal anhydramnios is generally defined as absent fluid caused by fetal renal failure by approximately 22 weeks of gestation. Its principal causes are bilateral renal agenesis, severe cystic or dysplastic kidney disease, and lower urinary tract obstruction accompanied by irreversible renal damage. Other causes of absent fluid include preterm prelabor rupture of membranes and severe uteroplacental insufficiency. These conditions have different prognoses and therapeutic options; therefore, accurately identifying the etiology is essential before counseling the family or considering fetal intervention. Amniotic fluid is critical for pulmonary development. The fetal lungs normally secrete fluid into the tracheobronchial tree, creating internal pressure that promotes airway branching and lung growth. In the absence of surrounding amniotic fluid, lung fluid can escape more readily through the fetal airway during glottic opening. Loss of intrapulmonary pressure, restriction of fetal breathing movements, and compression of the fetal thorax interfere with normal lung expansion. Persistent anhydramnios can consequently produce pulmonary hypoplasia, pulmonary vascular abnormalities, severe neonatal respiratory failure, and persistent pulmonary hypertension. The greatest vulnerability appears to occur during the canalicular phase of lung development, although clinically important pulmonary injury can also develop when anhydramnios begins after 22 weeks. The traditional view that fluid-dependent lung development is essentially complete by 22 weeks is not supported by the available clinical evidence. Persistent renal anhydramnios beginning later in the second trimester can still cause lethal pulmonary hypoplasia. Fetuses with previously normal fluid who develop anhydramnios between approximately 22 and 30 weeks may experience profound respiratory morbidity if the fluid deficit remains uncorrected. Restoration of amniotic fluid or successful relief of urinary obstruction may permit survival in selected cases. Gestational age at onset should therefore inform prognosis, but it should not be used as an absolute boundary beyond which anhydramnios is considered harmless or fetal treatment automatically futile. Prenatal ultrasound is the initial diagnostic examination. Evaluation should document whether any measurable pocket of fluid remains and should assess the kidneys, renal arteries, ureters, bladder, urethra, external genitalia, and the remainder of the fetal anatomy. Bilateral renal agenesis is suggested by absent kidneys and renal arteries, failure to visualize the bladder, and progressive loss of fluid. Dysplastic kidneys may appear enlarged, echogenic, cystic, or severely involuted. Lower urinary tract obstruction is characterized by an enlarged and thick-walled bladder, possible dilation of the ureters and renal collecting systems, and variable renal echogenicity or cystic dysplasia. A small or nonfilling bladder in an obstructed fetus may indicate advanced loss of renal function. The evaluation must also exclude ruptured membranes, particularly when renal anatomy does not clearly explain the absent fluid. Maternal history, sterile speculum examination, and biochemical testing of vaginal fluid may be required. A detailed anatomic examination is important because associated malformations may indicate a syndromic condition, change the expected outcome, or preclude intensive neonatal treatment. Severe anhydramnios can limit sonographic visualization; a diagnostic amnioinfusion may temporarily restore an acoustic window, confirm membrane integrity, improve assessment of fetal anatomy, and clarify the presence of renal tissue, renal blood flow, or additional abnormalities. Fetal magnetic resonance imaging can provide supplementary information about lung volume and anatomy when ultrasound remains inadequate. Genetic assessment is an important component of the evaluation because renal agenesis, cystic renal disease, dysplasia, and obstructive uropathy may be associated with chromosomal abnormalities or single-gene disorders. Testing may include karyotyping, chromosomal microarray analysis, targeted testing, multigene panels, or exome sequencing, depending on the phenotype and family history. A nondiagnostic genetic result does not exclude a genetic disorder, while identification of a pathogenic abnormality can substantially alter counseling regarding recurrence, associated disease, neonatal treatment, and the appropriateness of fetal intervention. Management should begin with multidisciplinary, nondirective counseling. Options include termination of pregnancy when legally and clinically available, expectant management with perinatal palliative care, and carefully selected fetal treatment. Counseling must separate pulmonary prognosis from renal prognosis. Restoring amniotic fluid may enable lung development, but it does not create functioning kidneys or reverse established renal dysplasia. A newborn who survives respiratory transition may still have end-stage kidney disease requiring immediate and continuous renal replacement therapy. The relevant outcome is therefore not simply live birth or early respiratory survival, but the possibility of prolonged hospitalization, dialysis, serious complications, kidney transplantation, and an acceptable long-term quality of life. Serial amnioinfusion is intended to reduce pulmonary hypoplasia by repeatedly replacing the absent fluid with warmed isotonic solution under ultrasound guidance. Treatment generally begins before 26 weeks and is repeated according to fluid loss and gestational age, often at intervals of several days to approximately one week. The objective is to maintain a fluid volume compatible with continued lung growth until delivery. In carefully selected fetuses with isolated bilateral renal agenesis, serial amnioinfusions have clearly demonstrated that lethal pulmonary hypoplasia is not inevitable. Among 17 live-born infants treated prenatally, 14, or 82%, survived for at least 14 days and underwent placement of dialysis access. Short-term respiratory success, however, did not translate into comparable long-term survival. Only six of the 17 live-born infants, or 35%, survived to hospital discharge while receiving chronic peritoneal dialysis. Subsequent deaths occurred from infectious and cardiopulmonary complications. Neurologic injury, including stroke, emerged as a particularly concerning complication among infants receiving dialysis. Hypotension, infection, nutritional failure, prematurity, cardiovascular instability, and technical difficulties with dialysis access also contributed to morbidity. At the time these outcomes were reported, none of the surviving children had yet undergone kidney transplantation. Transplantation generally requires sufficient somatic growth, and the absence or severe abnormality of the lower urinary tract can complicate urinary reconstruction. Prenatal treatment also carries obstetric risks. Preterm prelabor rupture of membranes occurred in approximately 61% of treated pregnancies, chorioamniotic separation in 28%, and vaginal bleeding in 22%. All treated pregnancies delivered prematurely, with a median gestational age of approximately 32 weeks. Greater gestational age and higher birth weight were associated with better neonatal survival, while premature membrane rupture reduced the interval available for treatment and lung growth. Serious maternal injury was uncommon, but repeated invasive procedures may cause discomfort, hospitalization, infection, bleeding, membrane complications, fetal loss, and spontaneous preterm delivery. Maternal safety and neonatal benefit must therefore be reassessed throughout treatment. Lower urinary tract obstruction represents a different therapeutic situation because relieving the obstruction may restore fetal urine production when renal function remains sufficiently preserved. Vesicoamniotic shunting and fetal cystoscopic treatment can decompress the bladder and potentially replenish amniotic fluid naturally. These interventions may improve perinatal survival, but they do not reliably preserve long-term renal function. Vesicoamniotic shunts may dislodge, migrate, retract, or become obstructed and can cause fetal ascites, abdominal-wall injury, membrane rupture, preterm labor, or fetal death. Available evidence suggests improved survival during the perinatal period but no established improvement in survival beyond infancy or in renal function at two years. Selection for intervention in lower urinary tract obstruction should therefore consider gestational age, bladder appearance, renal echogenicity, cystic dysplasia, urinary biochemistry when obtainable, associated anomalies, and evidence of residual urine production. A severely damaged urinary system may not recover after decompression. Conversely, successful correction of an obstruction with resolution of anhydramnios may reduce pulmonary injury and improve the opportunity for neonatal treatment. When obstruction cannot be corrected or renal failure persists, serial amnioinfusion may theoretically support lung development, but the child will still face the consequences of advanced kidney disease. Postnatal care requires immediate access to advanced respiratory, nephrology, surgical, and intensive-care support. Lung-protective ventilation, high-frequency ventilation, inhaled nitric oxide, cardiovascular support, and treatment of pulmonary hypertension may be necessary. Extracorporeal support cannot compensate for an extreme absence of functional lung tissue and may be inappropriate when recovery is not physiologically possible. If respiratory stabilization succeeds, peritoneal dialysis is generally the preferred long-term renal replacement strategy, although very low birth weight, abdominal complications, infection, hypotension, and lack of usable urinary anatomy can make treatment difficult. Anhydramnios should ultimately be understood as a time-sensitive, etiologically diverse condition rather than a uniformly lethal diagnosis. Prenatal fluid restoration can mitigate pulmonary hypoplasia and permit short-term survival in selected fetuses, but it transfers the principal threat from respiratory failure to severe chronic renal disease and its complications. Current evidence supports comprehensive diagnostic evaluation, genetic testing, transparent counseling, and individualized decision-making. Serial amnioinfusion for renal agenesis or irreversible fetal renal failure should remain restricted to highly specialized, ethically supervised treatment protocols with mandatory long-term follow-up. Meaningful counseling must present both the possibility of pulmonary rescue and the substantial probability of prematurity, dialysis-dependent survival, neurologic injury, prolonged hospitalization, and death before transplantation. References: 1- Jelin AC, Sagaser KG, Forster KR, Ibekwe T, Norton ME, Jelin EB. Etiology and management of early pregnancy renal anhydramnios: Is there a place for serial amnioinfusions? Prenat Diagn. 40(5):528-537, 2020 2- Atkinson MA, Jelin EB, Baschat A, Blumenfeld YJ, Chmait RH, O'Hare E, Moldenhauer JS, Zaretsky MV, Miller RS, Ruano R, Gonzalez JM, Johnson A, Mould WA, Davis JM, Hanley DF, Keiser AM, Rosner M, Miller JL. Design and Protocol of the Renal Anhydramnios Fetal Therapy (RAFT) Trial. Clin Ther. 44(8):1161-1171, 2022 3- Miller JL, Baschat AA, Atkinson MA. Fetal Therapy for Renal Anhydramnios. Clin Perinatol. 49(4):849-862, 2022 4- Miller JL, Baschat AA, Rosner M, Blumenfeld YJ, Moldenhauer JS, Johnson A, Schenone MH, Zaretsky MV, Chmait RH, Gonzalez JM, Miller RS, Moon-Grady AJ, Bendel-Stenzel E, Keiser AM, Avadhani R, Jelin AC, Davis JM, Warren DS, Hanley DF, Watkins JA, Samuels J, Sugarman J, Atkinson MA. Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial. JAMA. 330(21):2096-2105, 2023 5- Roberts AW, Clement M, Lopez SM, Swinford R, Pacora Portella P, Hernandez-Andrade E, Rysavy M, Johnson A. New Anhydramnios after 22 Weeks and Pulmonary Hypoplasia. Fetal Diagn Ther. 52(6):561-567, 2025 6- Pacora-Portella P, Hernandez-Andrade E, Johnson A. Fetal Therapy for Renal Anomalies and Anhydramnios. Clin Obstet Gynecol. 68(3):399-414, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|